LC-MS/MS method for simultaneous quantification of the first-line anti-tuberculosis drugs and six primary metabolites in patient plasma: Implications for therapeutic drug monitoring-Reference-Cited by-同舟云学术

LC-MS/MS method for simultaneous quantification of the first-line anti-tuberculosis drugs and six primary metabolites in patient plasma: Implications for therapeutic drug monitoring

Published:2021-11 Issue: Volume:1185 Page:122986
ISSN:1570-0232
Container-title:Journal of Chromatography B
language:en
Short-container-title:Journal of Chromatography B

Author:

Kivrane Agnija,Grinberga Solveiga,Sevostjanovs Eduards,Igumnova Viktorija,Pole Ilva,Viksna Anda,Bandere Dace,Krams Alvils,Cirule Andra,Pugovics Osvalds,Ranka Renate

Funder

Latvijas Zinātnes Padome

Publisher

Elsevier BV

Subject

Cell Biology,Clinical Biochemistry,Biochemistry,General Medicine,Analytical Chemistry

Reference33 articles.

1. Global tuberculosis report 2020. World Health Organization (2020) https://www.who.int/publications/i/item/9789240013131.

2. Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017 update) . World Health Organization (2017) https://www.who.int/tb/publications/2017/dstb_guidance_2017/en/.

3. Therapeutic drug monitoring in the treatment of tuberculosis: an update;Alsultan;Drugs,2014

4. Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus;Babalik;Antimicrob. Agents. Chemother.,2013

5. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients;McIlleron;Antimicrob. Agents. Chemother.,2006

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships;Frontiers in Pharmacology;2024-03-22

2. Exploring Variability in Rifampicin Plasma Exposure and Development of Anti-Tuberculosis Drug-Induced Liver Injury among Patients with Pulmonary Tuberculosis from the Pharmacogenetic Perspective;Pharmaceutics;2024-03-12

3. Development and Validation of a UPLC-MS/MS Method for Therapeutic Drug Monitoring, Pharmacokinetic and Stability Studies of First-Line Antituberculosis Drugs in Urine;Molecules;2024-01-09

4. Protein binding investigation of first-line and second-line antituberculosis drugs;International Journal of Antimicrobial Agents;2023-12

5. New approach to rifampicin stability and first-line anti-tubercular drug pharmacokinetics by UPLC-MS/MS;Journal of Pharmaceutical and Biomedical Analysis;2023-10